国药一致：前三季度净利润同比下降10.18%

Core Viewpoint - The company reported a decline in both revenue and net profit for the third quarter and the first three quarters of the year, indicating ongoing challenges in the distribution business due to policy and market competition pressures [1] Financial Performance - In Q3, the company achieved total revenue of 18.328 billion, a year-on-year decrease of 1.89% [1] - The net profit attributable to shareholders in Q3 was 291 million, down 9.58% year-on-year [1] - For the first three quarters, total revenue reached 55.124 billion, reflecting a 2.38% year-on-year decline [1] - The net profit attributable to shareholders for the first three quarters was 957 million, a decrease of 10.18% year-on-year [1] Business Challenges - The distribution business continues to face policy and market competition pressures, although there has been a stabilization and recovery in distribution revenue through ongoing business structure optimization [1] - Increased credit impairment losses due to longer repayment cycles from some downstream customers have contributed to the decline in profits [1]